行情

GNMK

GNMK

GenMark诊断
NASDAQ

实时行情|Nasdaq Last Sale

5.44
-0.14
-2.51%
盘后: 5.44 0 0.00% 16:00 11/21 EST
开盘
5.60
昨收
5.58
最高
5.66
最低
5.43
成交量
14.11万
成交额
--
52周最高
8.37
52周最低
3.580
市值
3.16亿
市盈率(TTM)
-6.3641
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GNMK 新闻

  • GenMark Diagnostics to Participate in Upcoming Investor Conferences
  • GlobeNewswire.11/13 21:05
  • Edited Transcript of GNMK earnings conference call or presentation 6-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.11/12 14:56
  • Raymond James Maintains Outperform on GenMark Diagnostics, Raises Price Target to $9
  • Benzinga.11/07 17:33
  • Why GenMark Diagnostics, Inc. (NASDAQ:GNMK) Could Be Worth Watching
  • Simply Wall St..11/07 12:22

更多

所属板块

先进医疗设备和技术
+0.69%
医疗设备和用品
+0.17%

热门股票

名称
价格
涨跌幅

GNMK 简况

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.
展开

Webull提供GenMark Diagnostics, Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。